MA53904A - Composés contenant du deutérium - Google Patents

Composés contenant du deutérium

Info

Publication number
MA53904A
MA53904A MA053904A MA53904A MA53904A MA 53904 A MA53904 A MA 53904A MA 053904 A MA053904 A MA 053904A MA 53904 A MA53904 A MA 53904A MA 53904 A MA53904 A MA 53904A
Authority
MA
Morocco
Prior art keywords
compounds containing
containing deuterium
deuterium
compounds
Prior art date
Application number
MA053904A
Other languages
English (en)
French (fr)
Inventor
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of MA53904A publication Critical patent/MA53904A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053904A 2018-10-18 2019-10-17 Composés contenant du deutérium MA53904A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds

Publications (1)

Publication Number Publication Date
MA53904A true MA53904A (fr) 2021-08-25

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053904A MA53904A (fr) 2018-10-18 2019-10-17 Composés contenant du deutérium

Country Status (19)

Country Link
US (2) US12152087B2 (enExample)
EP (1) EP3866931B1 (enExample)
JP (2) JP7603199B2 (enExample)
KR (1) KR102848971B1 (enExample)
CN (1) CN112930214B (enExample)
AU (1) AU2019362389B2 (enExample)
BR (1) BR112021007060A2 (enExample)
CA (1) CA3116198A1 (enExample)
DK (1) DK3866931T3 (enExample)
ES (1) ES2942468T3 (enExample)
FI (1) FI3866931T3 (enExample)
HU (1) HUE061801T2 (enExample)
IL (1) IL282231B2 (enExample)
MA (1) MA53904A (enExample)
MX (1) MX2021004474A (enExample)
PL (1) PL3866931T3 (enExample)
SG (1) SG11202103726RA (enExample)
WO (1) WO2020079165A1 (enExample)
ZA (1) ZA202102492B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (en) * 2021-06-01 2025-05-21 Synthon B.V. Process for making melflufen or a salt thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
US20240307480A1 (en) 2021-07-08 2024-09-19 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
JP6284945B2 (ja) * 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
JP6704252B2 (ja) 2013-02-05 2020-06-03 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Also Published As

Publication number Publication date
ES2942468T3 (es) 2023-06-01
US12152087B2 (en) 2024-11-26
SG11202103726RA (en) 2021-05-28
CN112930214B (zh) 2025-05-16
US20250115637A1 (en) 2025-04-10
AU2019362389A1 (en) 2021-06-03
JP2024150488A (ja) 2024-10-23
JP2022512736A (ja) 2022-02-07
CA3116198A1 (en) 2020-04-23
MX2021004474A (es) 2021-08-24
KR20210078487A (ko) 2021-06-28
BR112021007060A2 (pt) 2021-07-20
IL282231B2 (en) 2025-07-01
WO2020079165A1 (en) 2020-04-23
US20210388024A1 (en) 2021-12-16
IL282231A (en) 2021-05-31
FI3866931T3 (fi) 2023-05-10
IL282231B1 (en) 2025-03-01
AU2019362389B2 (en) 2024-12-12
HUE061801T2 (hu) 2023-08-28
EP3866931B1 (en) 2023-02-15
CN112930214A (zh) 2021-06-08
DK3866931T3 (da) 2023-04-24
ZA202102492B (en) 2024-04-24
KR102848971B1 (ko) 2025-08-21
PL3866931T3 (pl) 2023-06-19
EP3866931A1 (en) 2021-08-25
JP7603199B2 (ja) 2024-12-20

Similar Documents

Publication Publication Date Title
IL286833A (en) Compositions containing brazzein
PL3844147T3 (pl) Związki chemiczne
EP3836923A4 (en) PYRROLO-DIPYRIDINE COMPOUNDS
MA52489A (fr) Nouveaux composés
MA52948A (fr) Composés
EP3720430A4 (en) BENZOCARBONYL COMPOUNDS
EP3802467A4 (en) SPIROCYCLIC COMPOUNDS
MA55131A (fr) Nouveaux composés hétérocycliques
EP3781156A4 (en) SPIROCYCLIC COMPOUNDS
MA51669A (fr) Composés
MA44233A (fr) Nouveaux composés
EP3494121A4 (en) CONTINUOUS CONNECTIONS
MA53003A (fr) Composés
DK3692040T3 (da) Kemiske forbindelser
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
DK3866931T3 (da) Forbindelser indeholdende deuterium
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
EP3445750A4 (en) THERAPEUTIC COMPOUNDS
MA47420A (fr) Composés inhibiteurs d'oga
EP3315430A4 (en) CONTAINER
EP3707181A4 (en) HARDENABLE COMPOSITIONS WITH THIOL COMPOUNDS
EP3728289A4 (en) OPTIMIZED CONNECTIONS
EP3464336A4 (en) LINKS
EP3897732A4 (en) COMPOSITION CONTAINING CANNABINOIDS
MA52946A (fr) Composés